Attended Mark G Kris lecture on Lung Cancer (KRIS IS FROM MSKCC)
Now genetic sequencing is important
Prescribe the following
1) EGFR-------------ERLOTINIB, GEFITINIB
2) ALK-----------------CRIZOTINIB
3) HER-2--------------HERCEPTIN, LAPATINIB
4) BRAF -------------------VEMURAFENIB
5) ROS-1-----------------CRIZOTINIB (AGAIN)
6) RET--------------------------VANDETANIB (CABOZANTINIB)
7)MET------------------------CRIZOTINIB (AGAIN)
NICE THE PRESCRIPTION SPELLING OUT ONLY THE GENE SEQUENCING, AND LET YOUR PHARMACIST DO THE REST.
QUESTION: COULD THESE DRIVER GENE ABNORMALITIES BE THE SAME IN TRIPLE NEGATIVE BREAST CANCER?
A blog about research, awareness, prevention, treatment and survivorship of Breast Cancer and all cancers, including targeted scientific research and a grassroots approach to increase screening for cancer, especially in the low income and under-insured population of El Paso, Texas, with a view to expand this new health care model to many other 'minority' populations across the United States and beyond
Showing posts with label ROS-1. Show all posts
Showing posts with label ROS-1. Show all posts
Thursday, December 13, 2012
Labels:
ALK,
BRAF,
cabozantine,
crizotinib,
crozotinib,
EGFR,
erlotinib,
gefitinib,
HER-2,
herceptin,
KRIS,
lapatinib,
lung cancer,
Met,
RET,
ROS-1,
vandetanib,
vemurafenib
Subscribe to:
Posts (Atom)